COSCIENS Biopharma (TSE:CSCI) has released an update.
COSCIENS Biopharma Inc. reported increased revenues and a net loss in Q2 2024, with a strong cash position of $27.8 million. The company is progressing with post-merger integration and cost-saving strategies, focusing on growth through its diversified biopharmaceutical portfolio. Notably, COSCIENS anticipates releasing pivotal data from the DETECT-Trial for macimorelin, a diagnostic for childhood-onset growth hormone deficiency, in the third quarter.
For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.
